自拟温脾清肠汤治疗慢性溃疡性结肠炎56例

以自拟温脾清肠汤治疗慢性溃疡性结肠炎 5 6例 ,并以甲硝唑、黄连素、甲氰咪呱等治疗2 4例作对照 ,1 5d为 1个疗程 ,经 3个疗程治疗 ,2者治愈率、有效率比较均有显著性差异(P <0 .0 5 ) ,自拟温脾清肠汤为优     

健脾清肠汤治疗慢性溃疡性结肠炎60例

<正>慢性溃疡性结肠炎是一种原因未明的非特异性炎性肠病,临床以腹泻、黏液脓血便、腹痛为特征。该病病程长,起病隐匿,反复发作,缠绵难愈。近年来,我们应用健脾清肠汤治疗慢性溃疡性结肠炎取得较好疗效。现报道如下:     

疡愈汤保留灌肠治疗溃疡性结肠炎56例

溃疡性结肠炎可以发生在任何年龄人群,但以青壮年多见。临床表现以腹痛、腹泻、粘液血便、水样便、粘液便为主,轻者每日2~3次,重者可达每日10~20余次。有的病例主要以便血为主,或为粘液脓血便,也可为血水而无粪质。腹痛一般为轻到中度,常局限于下腹部或左下腹部,有疼痛-便意-便     

清肠化湿汤治疗溃疡性结肠炎的临床效果及对患者肠黏膜损伤和肠道微生态的影响

目的 探究清肠化湿汤治疗溃疡性结肠炎患者的临床效果及对患者肠黏膜损伤和肠道微生态的影响。方法 选择2018年5月至2020年5月收治的100例溃疡性结肠炎患者作为研究对象,根据计算机随机化法将其分为对照组（n=50）和试验组（n=50）。对照组采取基础治疗+美沙拉嗪,试验组则同时配合清肠化湿汤治疗。比较两组的临床疗效、中医证候积分、肠黏膜损伤程度评分、肠道微生态指标、临床指标、不良反应发生情况。结果 试验组的治疗总有效率为94.00%,显著高于对照组的78.00%,差异具有统计学意义（P<0.05）。治疗前,两组的里急后重、腹泻、腹痛、脓血便积分及Baron内镜评分比较,差异无统计学意义（P>0.05）;治疗后,两组的里急后重、腹泻、腹痛、脓血便积分及Baron内镜评分均低于治疗前,且试验组低于对照组（P<0.05）。治疗前,两组的乳酸杆菌、双歧杆菌、肠球菌、大肠杆菌数量比较,差异无统计学意义（P>0.05）;治疗后,两组的乳酸杆菌、双歧杆菌水平均高于治疗前,肠球菌、大肠杆菌数量均低于治疗前,且试验组优于对照组,差异具有统计学意义（P<0.05）。治疗前,...     

血管性认知障碍患者血清BACE1、sRAGE水平变化

目的探讨血清淀粉蛋白前B位分解酶1（BACE1）、糖基化终末产物受体可溶性片段（sRAGE）在血管性认知障碍患者中的变化及其临床意义。方法选取2012年1月至12月收治的89例缺血性脑卒中患者,其中无认知障碍的患者（脑卒中组）26例,血管性轻度认知障碍非痴呆组50例,血管性痴呆组13例。另选20例正常健康人作为对照组。检测并比较各组血清BACE1、sRAGE水平。结果脑卒中组与对照组血清sRAGE、BACE1水平相近,差异均无统计学意义（P均〉0．05）。与脑卒中组和对照组相比,血管性轻度认知障碍组、血管性痴呆组血清sRAGE水平明显下降（P均〈0．05）,血清BACEl水平明显增高（P均〈0．05）。结论BACE1、sRAGE在血管性认知障碍患者中早期就有变化,可作为卒中后认知障碍早期诊断的分子生物学标记物。     

消溃清肠汤灌肠辅助治疗溃疡性结肠炎的效果观察

[目的]探讨中药消溃清肠汤灌肠治疗溃疡性结肠炎的效果。[方法]将60例溃疡性结肠炎病人随机分为对照组和治疗组,两组均采用西医常规治疗和口服中药治疗,治疗组在此基础上采用消溃清肠汤灌肠治疗,治疗4周后比较两组疗效。[结果]治疗组有效率为90.0%,对照组有效率为70.0%,两组疗效比较,差异有统计学意义（P〈0.01）。[结论]应用中药消溃清肠汤灌肠辅助治疗溃疡性结肠炎疗效显著,且不良反应少。     

消溃清肠汤灌肠辅助治疗溃疡性结肠炎的效果观察

[目的]探讨中药消溃清肠汤灌肠治疗溃疡性结肠炎的效果。[方法]将60例溃疡性结肠炎病人随机分为对照组和治疗组,两组均采用西医常规治疗和口服中药治疗,治疗组在此基础上采用消溃清肠汤灌肠治疗,治疗4周后比较两组疗效。[结果]治疗组有效率为90.0%,对照组有效率为70.0%,两组疗效比较,差异有统计学意义(P<0.01)。[结论]应用中药消溃清肠汤灌肠辅助治疗溃疡性结肠炎疗效显著,且不良反应少。     

布拉氏酵母菌对重症肺炎患儿血浆D-乳酸、I-FABP水平的影响分析

目的 研究布拉氏酵母菌对重症肺炎患儿血浆D-乳酸以及肠型脂肪酸结合蛋白(IFABP)水平的影响.方法 选取2018年1月～2019年1月于我院接受治疗的重症肺炎患儿86例,随机分为对照组观察组各43例.对照组采用头孢呋辛钠+甲泼尼龙注射治疗,观察组在上述基础上辅助布拉氏酵母菌治疗,对比两组治疗前后炎性因子、血浆D-乳酸...     

清溃愈疡汤灌肠联合美沙拉嗪治疗湿热型溃疡性结肠炎的临床研究

目的 探讨清溃愈疡汤灌肠联合美沙拉嗪对湿热型溃疡性结肠炎(UC)患者中医证候积分、肠道屏障功能及Toll样受体4(TLR4)、核因子κB(NF-κB)水平的影响。方法 选取110例湿热型UC患者作为研究对象,根据治疗方式的不同分为美沙拉嗪组(采用美沙拉嗪治疗)35例、联合益生菌组(采用益生菌联合美沙拉嗪治疗)35例、联合清溃愈疡汤组(采用清溃愈疡汤灌肠联合美沙拉嗪治疗)40例。3组患者均治疗4周,比较3组患者治疗前后的中医证候积分、Baron内镜评分、肠道屏障功能指标及TLR4、NF-κB水平变化。结果 治疗前,3组患者腹痛积分、腹泻积分、脓血便积分、Baron内镜评分、血清D-乳酸(D-LA)水平、二胺氧化酶(DAO)水平、乳果糖/甘露醇(L/M)值以及TLR4、NF-κB蛋白的平均光密度值比较,差异均无统计学意义(P>0.05);治疗后,3组患者腹痛积分、腹泻积分、脓血便积分、Baron内镜评分、血清D-LA水平、DAO水平、L/M值以及TLR4、NF-κB蛋白的平均光密度值均低于治疗前,且联合清溃愈疡汤组低于联合益生菌组和美沙拉嗪组,联合益生菌组低于美沙拉嗪组,差异均有统计...     

Mechanism of Jianpi Qingchang Huashi Recipe in treating ulcerative colitis: A study based on network pharmacology and molecular docking

BACKGROUNDUlcerative colitis (UC) is a refractory intestinal disease with alternating onset and remission and a long disease course, which seriously affects the health and quality of life of patients. The goal of treatment is to control clinical symptoms, induce and maintain remission, promote mucosal healing, and reduce recurrence. Clinical trials have shown unsatisfactory clinical response rates. As a supplementary alternative medicine, traditional Chinese medicine has a rich history and has shown good results in the treatment of UC. Because of the quality of herbal medicine and other factors, the curative effect of traditional Chinese medicine is not stable enough. The mechanism underlying the effect of Jianpi Qingchang Huashi Recipe (JPQCHSR) on inducing UC mucosal healing is not clear.AIMTo investigate the potential mechanism of JPQCHSR for the treatment of UC based on network pharmacology and molecular docking.METHODSTraditional Chinese Medicine Systems Pharmacology Database and Analysis Platform was used to extract the active components and action targets of JPQCHSR, and the target names were standardized and corrected through UniProt database. The related targets of UC were obtained through GeneCards database, and the intersection targets of drugs and diseases were screened by jvenn online analysis tool. The visual regulatory network of "Traditional Chinese medicine-active components-target-disease" was constructed using Cytoscape software, the protein interaction network was constructed using STRING database, and enrichment analysis of gene ontology and Kyoto Encyclopedia of Genes and Genomes pathways was conducted through R software. At last, the active components were docked with the core target through SYBYL-X 2.1.1 software.RESULTSThrough database analysis, a total of 181 active components, 302 targets and 205 therapeutic targets were obtained for JPQCHSR. The key compounds include quercetin, luteolin, kaempferol, etc. The core targets involved STAT3, AKT1, TP53, MAPK1, MAPK3, JUN, TNF, etc. A total of 2861 items were obtained by GO enrichment analysis, and 171 items were obtained by KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway enrichment analysis. The results of molecular docking showed that the key active components in JPQCHSR had certain affinity with the core target.CONCLUSIONThe treatment of UC with JPQCHSR is a complex process of multi-component, multi-target and multi-pathway regulation. The mechanism of this Recipe in the treatment of UC can be predicted through network pharmacology and molecular docking, so as to provide theoretical reference for it to better play its therapeutic role.     

Serum levels of C-reactive protein in Crohn''s disease and ulcerative colitis

Prospective measurements were made of serum C-reactive protein levels and erythrocyte sedimentation rate in sixty-four patients with Crohn's disease and fifty with ulcerative colitis. The results were related to clinical assessment of disease activity. C-reactive protein levels were raised in both groups but were significantly higher in Crohn's disease than ulcerative colitis for all categories of disease severity: with mild disease the median and range of C-reactive protein concentration were 4, 0-65 mg/l in Crohn's disease v. 0, 0-15 mg/l in ulcerative colitis, P less than 0.01; in moderate disease the values were 15, 1-100 mg/l v. 3, 0-29 mg/l respectively, P less than 0.05 and in cases of severe disease, 85, 15-183 mg/l v. 12, 2-33 mg/l respectively, P less than 0.001. Erythrocyte sedimentation rate was also higher in Crohn's disease but did not closely reflect disease activity in individual patients. C-reactive protein levels corresponded closely with clinical and pathological indices of relapse, remission and response to therapy in patients with Crohn's disease. The precise assay of serum C-reactive protein provides an objective criterion of inflammatory activity, which may be useful in the assessment, management and study of Crohn's disease.     

Effects of flaxseed and flaxseed oil supplement on serum levels of inflammatory markers,metabolic parameters and severity of disease in patients with ulcerative colitis

ObjectiveThe present study aimed to evaluate the possible effect of grounded flaxseed and flaxseed oil on serum levels of inflammatory markers, metabolic parameters, and the severity of disease in patients with UC.MethodsIn this open-labeled randomized controlled trial, 90 UC patients were randomly assigned to one of the 3 groups for 12 weeks: grounded flaxseed (GF; 30 g/day), flaxseed oil (FO; 10 g/day) and control group. The weight, waist circumference, systolic and diastolic blood pressure, serum inflammatory markers (interleukin-6 (IL-6), interferon gamma (INF-γ), transforming growth factor beta (TGF-β), and Erythrocyte Sedimentation Rate (ESR)), and fecal calprotectin were measured at the baseline and end of the study.ResultsTotally, 75 patients (43 men and 32 women) with a mean age of 31.54 ± 9.84 years participated in the present study. Comparing the change of the variables indicated a significant decrease in fecal calprotectin (P < 0.001), Mayo score (P < 0.001), ESR (P < 0.001), INF-γ (P < 0.001), IL-6 (P < 0.001), waist circumference (P = 0.02), Diastolic Blood Pressure (DBP) (P < 0.001), and Systolic Blood Pressure (SBP) (P < 0.001) and a significant increase in TGF-β (P < 0.001) and Inflammatory Bowel Disease Questionnaire-Short form (IBDQ-9) score (P < 0.001) in the GF and FO groups compared to the control. No difference was obvious between the FO and GF groups except for TGF-β.ConclusionThe present study showed that both flaxseed and flaxseed oil, attenuate inflammatory markers, disease severity, blood pressure, and WC. However, the effect of flaxseed on weight and BMI was not evident.     

Phospholipase A2 in serum and colonic mucosa in ulcerative colitis.

Group II phospholipase A2 is involved in the pathogenesis of various inflammatory diseases and in the host defence against bacteria. The enzyme is expressed in the epithelial cells of colonic mucosa in ulcerative colitis. In this study, we measured the concentration of group II phospholipase A2 in serum and colonic mucosa of patients with ulcerative colitis of different severity and of control patients without any inflammatory disease. The activity of ulcerative colitis was assessed by endoscopy. The concentration of group II phospholipase A2 was measured with an immunoassay. The concentrations of group II phospholipase A2 in serum and colonic mucosa were significantly higher in patients with active and inactive ulcerative colitis than in controls. However, the group II phospholipase A2 levels did not separate patients with different disease activity. The concentration of group II phospholipase A2 in colonic mucosa corresponded with the mucosal inflammatory activity (higher in active colonic areas) intra-individually, but not between different patients with ulcerative colitis. Serum group II phospholipase A2 values were above the normal reference range more often than the values of 11 standard laboratory blood tests widely used for the follow-up of inflammatory activity in ulcerative colitis. These results indicate that the concentration of group II phospholipase A2 is increased in serum and colonic mucosa of patients with ulcerative colitis. The clinical value of the measurement of group II phospholipase A2 in the follow-up of ulcerative colitis remains to be clarified.